Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA Guidelines
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac394 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Jennifer H Ku und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University - Portland State University School of Public Health, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Mycobacterium avium-intracellulare Infection, Lung Diseases, Rifamycins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
Nontuberculous mycobacteria are environmental organisms that cause infections leading to chronic, debilitating pulmonary disease, among which Mycobacterium avium complex (MAC) is the most common species.
Methods
We described patterns of macrolide-based multidrug antibiotic therapies for MAC pulmonary disease (MAC-PD) in US Medicare beneficiaries with bronchiectasis between January 2006 and December 2014. MAC therapy was defined as a multidrug regimen containing a macrolide plus ≥1 other drug targeting MAC-PD (rifamycin, ethambutol, fluoroquinolone, or amikacin) prescribed concomitantly for >28 days.
Results
We identified 9189 new MAC therapy users, with a mean age (standard deviation) of 74 (6 years) at the start of therapy; 75% female and 87% non-Hispanic white. A guideline-based regimen (a macrolide, ethambutol, and rifamycin, with or without amikacin) was prescribed for 51% of new MAC therapy users at treatment start, of whom 41% were continuing guideline-based therapy at 6 months, and only 18% at 12 months. Of all new MAC therapy users, by 18 months only 11% were still receiving MAC treatment, 55% had discontinued therapy, and 34% were censored owing to death or the end of the study period.
Conclusions
Overall, nearly half of new MAC therapy users were prescribed a non–guideline-recommended macrolide-based therapy, including regimens commonly associated with promoting macrolide resistance. Treatment discontinuation was common, and once discontinued, only a few beneficiaries resumed therapy at a later time. Our study adds important data to the current literature on treatment patterns for MAC-PD among older US populations. Future research should examine treatment patterns using more contemporary data sources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oregon Health & Science University - Portland State University School of Public Health, Portland, Oregon, USA.
- Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
- Center to Improve Veteran Involvement in Care, Veterans Affairs Portland Healthcare System, Portland, Oregon, USA.
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada.
- Department of Respiratory Medicine, West Park Healthcare Centre, Toronto, Ontario, Canada.
ORCID-Profile: Jennifer H Ku
Zitieren
APA
Ku, J. H., Henkle, E., Carlson, K. F., Marino, M., Brode, S. K., Marras, T. K., & Winthrop, K. L. (2023). Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA Guidelines. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac394
Vancouver
Ku JH, Henkle E, Carlson KF, Marino M, Brode SK, Marras TK, et al. Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA Guidelines. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac394
BibTeX
@article{Ku2023,
author = {Ku, Jennifer H and Henkle, Emily and Carlson, Kathleen F and Marino, Miguel and Brode, Sarah K and Marras, Theodore K and Winthrop, Kevin L},
title = {Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA Guidelines},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac394}
}
EUVIMED